Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Post by RTOon Apr 04, 2014 9:16am
187 Views
Post# 22410425

Warrants Terms - Existing & Proposed

Warrants Terms - Existing & ProposedOkay, lets clear this up once and for all, I will try to make it as simple as possible.  IMO, the warrants are trading "today" in anticipation of those proposed terms, subject to approval.  Please read both PR's carefully for a complete reference.

EXISTING TERMS:

From the PR 2011-08-26;  At the open on Tuesday, Aug. 30, 2011, 18 warrants will entitle the holder to acquire one Adherex share for $1.44. The warrants will expire at 5 p.m. (Toronto time) on March 30, 2016.

PROPOSED TERMS:

From the PR 2013-11-22;  An offer to holders of warrants issued by the company on or about April 30, 2010, and on or about March 29, 2011, a right to exchange such outstanding warrants for new unlisted warrants on a one-new-warrant-for-10-outstanding-warrants basis, with the new warrants having an exercise price per common share of 50 U.S. cents.


Bullboard Posts